Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Preliminary results of a phase Ib study combining ABT-199 and obinutuzumab in CLL

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ian Flinn (Sarah Cannon Cancer Institute, Nashville, TN) discusses the preliminary results of a phase Ib study (GP28331) combining GDC-0199 (ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL).